Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1652MXR

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29	JAN 02	STN pricing information for 2008 now available
NEWS 30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 32	JAN 28	MARPAT searching enhanced
NEWS 33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication

```
 NEWS 34  JAN 28  TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS 35  JAN 28  MEDLINE and LMEDLINE reloaded with enhancements
 NEWS 36  FEB 08  STN Express, Version 8.3, now available


 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2008

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 21:34:44 ON 14 FEB 2008

=> file CAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'CAPLUS' ENTERED AT 21:35:00 ON 14 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 14 Feb 2008  VOL 148 ISS 7
FILE LAST UPDATED: 13 Feb 2008  (20080213/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> e losartan
E1            1     LOSARTA/BI
E2            1     LOSARTAM/BI
E3         5490 --> LOSARTAN/BI
E4            1     LOSARTANK/BI
E5            1     LOSARTANS/BI
E6            1     LOSARTANT/BI
```

```
E7            2     LOSARTEN/BI
E8            2     LOSARTIN/BI
E9            1     LOSARTOAN/BI
E10           3     LOSARTON/BI
E11           2     LOSARTRAN/BI
E12           1     LOSASSO/BI

=> s E3
          5490 LOSARTAN/BI
             1 LOSARTANS/BI
L1        5490 LOSARTAN/BI
                  ((LOSARTAN OR LOSARTANS)/BI)

=> s l1 and polymorph
          8459 POLYMORPH
          9548 POLYMORPHS
         14667 POLYMORPH
                  (POLYMORPH OR POLYMORPHS)
L2          14 L1 AND POLYMORPH

=> d L1-5 ibib abs
'L1-999' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
```

```
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):ibib ab

L2   ANSWER 1 OF 14  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2007:761240  CAPLUS
DOCUMENT NUMBER:          147:166619
TITLE:                    Preparation of β-amino acid derivatives as
                          dipeptidyl peptidase-IV inhibitors
INVENTOR(S):              Sattigeri, Jitendra A.; Ahmed, Shahadat; Andappan,
                          Murugaiah M. S.; Sethi, Sachin; Sharma, Lalima; Pal,
                          Chanchal Kumar; Kandalkar, Sachin Ramesh; Mahajan,
                          Dipak C.; Kishore, Kaushal; Bhatia, Sumati; Gadhave,
                          Anil G.; Bansal, Vinay S.; Davis, Joseph Alexanand
PATENT ASSIGNEE(S):       Ranbaxy Laboratories Limited, India
SOURCE:                   PCT Int. Appl., 74pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
     WO 2007077508        A2    20070712    WO 2006-IB55006        20061221
     WO 2007077508        A3    20071025
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
              GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
              KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
              MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
              RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
              TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
          RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
              IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
              CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
              GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
              KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.:                    IN 2005-DE3520      A  20051230
OTHER SOURCE(S):          MARPAT 147:166619
AB   The invention relates to the preparation of β-amino acid derivs. I [A =
```

(hetero)aryl; E, E' = independently (CRaRb)n; n = 1-2; Ra, Rb = independently H, alk(en/yn)yl, cycloalkyl, (hetero)/aryl, heterocyclyl; RaCRb = optionally unsatd. ring; R = (un)substituted 2,5-diazabicyclo[2.2.1]hept-2-yl, (piperidin-4-yl)amino, -3-azabicyclo[3.1.0]hex-6-yl, etc.], and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs, prodrugs, metabolites, and N-oxides, as dipeptidyl peptidase-IV inhibitors. This invention also relates to pharmacol. compns. containing the compds. of the invention, and methods of treating diabetes, especially type 2 diabetes, as well as prediabetes, diabetic dyslipidemia, metabolic acidosis, ketosis, satiety disorders, and obesity. These inhibitors can also be used to treat conditions manifested by a variety of metabolic, neurol., anti-inflammatory, and autoimmune disorders like inflammatory disease, multiple sclerosis, rheumatoid arthritis; viral, cancer and gastrointestinal disorders. I can also be used for treatment of infertility arising due to polycystic ovary syndrome. Thus, coupling 4-amino-1-[(morpholin-4-yl)carbonyl]piperidine tosylate with (3R)-3-[N-(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoic acid and cleavage of tert-butoxycarbonyl group in the presence of TFA gave II•TFA . I were evaluated for their peptidase-IV inhibitory activity using a fluorometric assay (IC50 values in the range of 1 nm to 10 μM).

=> d l2 2-8 ibib ab

L2 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1155444 CAPLUS
DOCUMENT NUMBER: 145:477884
TITLE: Angiotensin II receptor antagonists
INVENTOR(S): Alani, Laman L.; Dubost, David C.; Foster, Bruce S.; Ghosh, Soumojeet; Jahansouz, Hossain; Pourkavoos, Nazaneen; Rege, Bhagwant; Tatavarti, Aditya
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 34pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006115834	A1	20061102	WO 2006-US14092	20060414
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006240247	A1	20061102	AU 2006-240247	20060414
CA 2604190	A1	20061102	CA 2006-2604190	20060414
EP 1874302	A1	20080109	EP 2006-750200	20060414
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2007CN04215	A	20071221	IN 2007-CN4215	20070924

PRIORITY APPLN. INFO.: US 2005-673086P P 20050420
WO 2006-US14092 W 20060414

AB The compds. of the present invention are polymorphic crystalline forms of the compound 2-butyl-4-chloro-1-[(2'-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid (I). Specifically, the compds. of the invention are selected from the group consisting of e.g., I, I-HCl Forms I through III and their monohydrate forms. I was prepared and converted to controlled release granules.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1004564 CAPLUS
DOCUMENT NUMBER: 143:292576
TITLE: Stabilization of a polymorphic form of losartan potassium
INVENTOR(S): Svete, Peter; Grahek, Rok; Humar, Vlasta; Husu-Kovacevic, Breda; Jerala-Strukelj, Zdenka
PATENT ASSIGNEE(S): Lek Pharmaceuticals D.D., Slovenia
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005084670	A1	20050915	WO 2005-EP2108	20050228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1729766	A1	20061213	EP 2005-707662	20050228
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 2007298108	A1	20071227	US 2007-590889	20070604

PRIORITY APPLN. INFO.: SI 2004-67 A 20040301
WO 2005-EP2108 W 20050228

AB Compns. were developed which stabilize an active pharmaceutical ingredient in polymorph form susceptible to degradation or interconversion into other polymorph forms, where stabilizing substance is conveniently among silicon dioxide, silicified microcryst. cellulose, magnesium oxide and polyethylene glycol. The polymorphic form of losartan potassium was stable when formulated with Syloid and PEG 6000.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:740317 CAPLUS
DOCUMENT NUMBER: 141:265973
TITLE: Preparation of polymorphic crystal forms of the antihypertensive agent losartan potassium

INVENTOR(S): Kumar, Pananchukunnath Manoj; Manikandan, Ramalingam; Singh, Romi Barat; Nagaprasad, Vishnubhotla; Malik, Rajiv
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076442	A1	20040910	WO 2004-IB516	20040227

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IN 2003-DE202 A 20030228

AB Processes for producing polymorphic crystal forms of losartan potassium (I), useful as an antihypertensive, are claimed as are the crystal polymorphs of I, their crystal-characterization data, and their use in pharmaceutical formulations.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:740288 CAPLUS
DOCUMENT NUMBER: 141:248753
TITLE: Preparation of losartan potassium polymorphs
INVENTOR(S): Boccignone, Andrea; Malpezzi, Luciana; Castaldi, Graziano; Allegrini, Pietro; Beltrame, Andrea
PATENT ASSIGNEE(S): Dinamite Dipharma S.P.A. In Abbreviate Form Dipharma S.P.A., Italy; Dipharma S.P.A.
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076406	A2	20040910	WO 2004-EP1717	20040220
WO 2004076406	A3	20050113		

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IT 2003-MI328 A 20030225

AB Losartan potassium polymorphs, identified as losartan potassium crystalline hydrate, losartan potassium amorphous and losartan potassium modification crystalline III, a process for their preparation, pharmaceutical compns. containing them and their use in therapy. Thus, losartan was dissolved in MeOh and treated with KHCO3 to give a losartan potassium polymorph III.

L2 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:733484 CAPLUS

DOCUMENT NUMBER: 142:127050

TITLE: Effect of enalapril and losartan on cytokines in patients with stable angina pectoris awaiting coronary artery bypass grafting and their interaction with polymorphisms in the interleukin-6 gene

AUTHOR(S): Trevelyan, Jasper; Brull, David J.; Needham, Edward W. A.; Montgomery, Hugh E.; Morris, Alan; Mattu, Raj K.

CORPORATE SOURCE: Department of Cardiology, University Hospitals of Coventry and Warwickshire, Coventry, UK

SOURCE: American Journal of Cardiology (2004), 94(5), 564-569 CODEN: AJCDAG; ISSN: 0002-9149

PUBLISHER: Excerpta Medica, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may have anti-inflammatory actions, an effect that could explain some of their beneficial effects on cardiovascular events in clin. trials. Coronary artery bypass grafting (CABG) is associated with a systemic inflammatory response and provides a convenient model to examine the effects of such agents. Genetic polymorphisms may be important in influencing the expression of cytokines, such as interleukin-6 (IL-6). We randomized men awaiting CABG to treatment with enalapril, losartan , or control for 2 mo before surgery. Systemic IL-6, IL-8, IL-10, and IL-1 receptor agonists were measured before and after surgery, and genotypes for the -174 G/C and -572 G/C IL-6 gene polymorphisms were determined Total release of the IL-1 receptor agonist was decreased 29% by enalapril and 31% by losartan (adjusted p = 0.041). IL-6 was decreased 17% by enalapril and 20% by losartan. Subjects possessing the -174 GG genotype produced 20% more IL-6 (adjusted p = 0.029). In these high producers of IL-6, release of IL-6 was decreased 51% by enalapril (adjusted p = 0.001) and 32% by losartan (adjusted p = 0.068). Release of IL-10 was nonsignificantly decreased 26% by enalapril and 21% by losartan, whereas IL-8 was not detected. In conclusion, enalapril and losartan significantly decreased release of the IL-1 receptor agonist after CABG. Enalapril produced a highly significant decrease of 51% in the release of IL-6 in patients identified as high producers of IL-6 by the -174 G/C polymorphism, whereas losartan has a similar but less marked effect. The production of IL-6 in this setting is influenced by the -174 G/C polymorphism.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:610104 CAPLUS

DOCUMENT NUMBER: 141:134092
TITLE: Telmisartan-simvastatin combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases
INVENTOR(S): Riedel, Axel; Sendra, Josep-Maria; Leiter, Josef M. E.; Kauschke, Stefan; Mark, Michael
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. Kg
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062729	A1	20040729	WO 2004-EP175	20040114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA				
DE 10301372	A1	20040729	DE 2003-10301372	20030116
DE 10335027	A1	20050217	DE 2003-10335027	20030731
AU 2004204353	A1	20040729	AU 2004-204353	20040114
CA 2513281	A1	20040729	CA 2004-2513281	20040114
US 2004259925	A1	20041223	US 2004-757295	20040114
EP 1587584	A1	20051026	EP 2004-701918	20040114
EP 1587584	B1	20070523		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006812	A	20051227	BR 2004-6812	20040114
JP 2006515877	T	20060608	JP 2006-500558	20040114
AU 2004260606	A1	20050210	AU 2004-260606	20040724
CA 2534006	A1	20050210	CA 2004-2534006	20040724
EP 1651213	A1	20060503	EP 2004-763484	20040724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1829511	A	20060906	CN 2004-80022096	20040724
BR 2004013165	A	20061003	BR 2004-13165	20040724
JP 2007500677	T	20070118	JP 2006-521497	20040724
MX 2005PA07559	A	20050921	MX 2005-PA7559	20050714
NO 2005003793	A	20050810	NO 2005-3793	20050810
MX 2006PA01322	A	20060504	MX 2006-PA1322	20060131
NO 2006000938	A	20060227	NO 2006-938	20060227

PRIORITY APPLN. INFO.:

DE 2003-10301372	A	20030116
DE 2003-10335027	A	20030731
DE 2003-10301371	A	20030116
US 2003-446695P	P	20030211
US 2003-503317P	P	20030916
DE 2003-10346260	A	20031006
DE 2003-10356815	A	20031205
WO 2004-EP175	W	20040114
WO 2004-EP8326	W	20040724

AB The invention discloses a method for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases, achieved by the improvement of endothelial function and the protection of organs, tissues and vessels when indications require a blood pressure check and a lipid level check, especially in patients that have been diagnosed with type 2 diabetes mellitus or if prediabetes is suspected. The method is also used for preventing diabetes and prediabetes and for the treatment of metabolic

syndrome and insulin resistance in patients with normal blood pressure. The method involves the combined administration of effective quantities of telmisartan, or a polymorph or salt thereof, and simvastatin. The invention also discloses suitable pharmaceutical compns. containing telmisartan, or a polymorph or salt thereof, and simvastatin, as a combined preparation for simultaneous, sep., or sequential use in the prophylaxis or treatment of the above diseases. Preparation of the sodium salt of telmisartan is described.

L2 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:606351 CAPLUS
DOCUMENT NUMBER: 141:134089
TITLE: Telmisartan-atorvastatin combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases
INVENTOR(S): Riedel, Axel; Sendra, Josep-Maria; Leiter, Josef M. E.; Kauschke, Stefan; Mark, Michael
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. Kg
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062557	A2	20040729	WO 2004-EP174	20040114
WO 2004062557	A3	20040916		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA				
DE 10301371	A1	20040805	DE 2003-10301371	20030116
DE 10335027	A1	20050217	DE 2003-10335027	20030731
AU 2004204352	A1	20040729	AU 2004-204352	20040114
CA 2513277	A1	20040729	CA 2004-2513277	20040114
US 2004259925	A1	20041223	US 2004-757295	20040114
EP 1587479	A2	20051026	EP 2004-701904	20040114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006455	A	20051206	BR 2004-6455	20040114
CN 1738617	A	20060222	CN 2004-80002407	20040114
JP 2006515614	T	20060601	JP 2006-500557	20040114
AU 2004260606	A1	20050210	AU 2004-260606	20040724
CA 2534006	A1	20050210	CA 2004-2534006	20040724
EP 1651213	A1	20060503	EP 2004-763484	20040724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1829511	A	20060906	CN 2004-80022096	20040724
BR 2004013165	A	20061003	BR 2004-13165	20040724
JP 2007500677	T	20070118	JP 2006-521497	20040724
ZA 2005003542	A	20060726	ZA 2005-3542	20050504
MX 2005PA07103	A	20050826	MX 2005-PA7103	20050629
IN 2005DN03073	A	20070112	IN 2005-DN3073	20050711
NO 2005003837	A	20050815	NO 2005-3837	20050815
MX 2006PA01322	A	20060504	MX 2006-PA1322	20060131
NO 2006000938	A	20060227	NO 2006-938	20060227

PRIORITY APPLN. INFO.:		
DE 2003-10301371	A	20030116
DE 2003-10335027	A	20030731

US 2003-446695P	P	20030211
US 2003-503317P	P	20030916
DE 2003-10346260	A	20031006
DE 2003-10356815	A	20031205
WO 2004-EP174	W	20040114
WO 2004-EP8326	W	20040724

AB The invention discloses a method for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases, achieved by the improvement of endothelial function and the protection of organs, tissues and vessels when indications require a blood pressure check and a lipid level check, especially in patients that have been diagnosed with type 2 diabetes mellitus or if prediabetes is suspected. The method is also used for preventing diabetes and prediabetes and for the treatment of metabolic syndrome and insulin resistance in patients with normal blood pressure. The method involves the combined administration of effective amts. of telmisartan, or a polymorph or salt thereof, and atorvastatin. The invention also discloses suitable pharmaceutical compns. containing telmisartan, or a polymorph or salt thereof, and atorvastatin, as a combined preparation for simultaneous, sep. or sequential use in the prophylaxis or treatment of the above diseases. Preparation of the sodium salt of telmisartan is described.

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	29.92	30.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.40	-6.40

FILE 'STNGUIDE' ENTERED AT 21:37:53 ON 14 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 8, 2008 (20080208/UP).

=> s l2 9-14 ibib ab
MISSING OPERATOR L2 9-14
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l2 9-14 ibib ab
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L2 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2004:414643 CAPLUS
DOCUMENT NUMBER:	140:412339
TITLE:	Crystalline form of losartan potassium
INVENTOR(S):	Reddy, Manne Satyanarayana; Eswaraiah, Sajja; Koppera, Ravinder Reddy; Reddy, Vajrala Venkata
PATENT ASSIGNEE(S):	Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
SOURCE:	U.S. Pat. Appl. Publ., 11 pp. CODEN: USXXCO
DOCUMENT TYPE:	Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004097568	A1	20040520	US 2003-629316	20030729
IN 2002MA00568	A	20070727	IN 2002-MA568	20020729

PRIORITY APPLN. INFO.: IN 2002-MA568 A 20020729

AB A compound that is a crystalline Form III of losartan potassium is provided. Also provided are compns. containing the compound and methods for its preparation For example, 125 g of trityl losartan (preparation given) was mixed with an aqueous solution containing 11 g of KOH, 125 mL water, and 1250 mL methanol until the reaction was complete. The solvent was distilled off the reaction solution under vacuum, and water (325 mL) added to the residual mass, stirred for 30 min, the pH adjusted to 8.2 to 8.8, and the mass filtered. The filtrate was washed with water, the water was distilled off, and the resulting residue was dissolved in methanol, the solvent distilled off, and the residual mass cooled to a temperature of 5 to 10°, filtered, and dried to yield crystalline polymorph Form III of losartan potassium (weight 43.0 g). The crystalline polymorph Form III of losartan potassium was also obtained from crystalline polymorph Form I of losartan potassium.

L2 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:287433 CAPLUS
DOCUMENT NUMBER: 136:58666
TITLE: Polymorphic transformation of losartan
AUTHOR(S): Elbary, A. Abd; Nafadi, M. M.; El-Khateeb, Mona A.
CORPORATE SOURCE: Department of pharmaceutics, Faculty of Pharmacy, Cairo University, Cairo, Egypt
SOURCE: Egyptian Journal of Pharmaceutical Sciences (2000), Volume Date 1999, 40(1), 49-59
CODEN: EJPSBZ; ISSN: 0301-5068
PUBLISHER: National Information and Documentation Centre
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Losartan was recrystd. from alc. solns. containing each of PEG 4000, PEG 6000, Tween 40, Tween 80, Myrj 59 and PVPK90 sep. Samples of the drug, with or without polymers or surfactants were investigated using DSC, XRD, IR and microphotographs to reveal the presence or absence of polymorphism. There were polymorphic changes of the drug with all the tested additives and all polymorphic forms are crystalline
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:90112 CAPLUS
DOCUMENT NUMBER: 126:297598
TITLE: Solubilities of losartan polymorphs
AUTHOR(S): Crocker, L. S.; McCauley, J. A.
CORPORATE SOURCE: Merck Research Laboratories, Rahway, NJ, 07065, USA
SOURCE: Pharmazie (1997), 52(1), 72
CODEN: PHARAT; ISSN: 0031-7144
PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The solubilities of the enantiotropic polymorphs I and II of losartan, an orally administered angiotensin II receptor

antagonist used in the treatment of hypertension, was determined to evaluate the free energy differences between the two forms. The solubilities of form I and II at 25-65° were 0.59-1.25 and 1.95-2.63 resp. Thus, form I has lower solubility and is more thermodynamically stable.

L2 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:890142 CAPLUS
DOCUMENT NUMBER: 123:313978
TITLE: Polymorphs of losartan potassium and a process for the preparation of polymorph forms I and II of losartan potassium
INVENTOR(S): Campbell, Gordon Creston, Jr.; Dwivedi, Anil M.; Levorse, Dorothy A.; McCauley, James A.; Raghavan, Krishnaswamy S.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA; du Pont de Nemours, E. I., and Co.; Dupont Merck Pharmaceutical Co.
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9517396	A1	19950629	WO 1994-US14768	19941221
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2179067	A1	19950629	CA 1994-2179067	19941221
AU 9514058	A	19950710	AU 1995-14058	19941221
AU 685898	B2	19980129		
EP 736021	A1	19961009	EP 1995-905449	19941221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09507075	T	19970715	JP 1994-517594	19941221
US 5608075	A	19970304	US 1995-371937	19950112
PRIORITY APPLN. INFO.:			US 1993-173440 A	19931223
			WO 1994-US14768 W	19941221

AB Polymorphic forms of losartan potassium, I, a known angiotensin II-inhibiting antihypertensive, are prepared Numerous spectral, thermal, and X-ray data of I form I and II are reported, and I-containing formulations are presented along with angiotensin II receptor inhibition data.

L2 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:116612 CAPLUS
DOCUMENT NUMBER: 120:116612
TITLE: Thermal analysis and solution calorimetry studies on losartan polymorphs
AUTHOR(S): Wu, Lei Shu; Gerard, Christine; Hussain, Munir A.
CORPORATE SOURCE: Du Pont Merck Pharm. Co., Wilmington, DE, 19880-0336, USA
SOURCE: Pharmaceutical Research (1993), 10(12), 1793-5
CODEN: PHREEB; ISSN: 0724-8741
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The existence of losartan (I) polymorphs was confirmed by solution calorimetry. The heat of transition was determined to be 1.74 kcal/mol from Form I to Form II. Form I is thermodynamically more stable

than Form II at ambient temperature Form II could convert to Form I during storage at ambient temperature since the conversion is exothermic.

L2 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:525045 CAPLUS
DOCUMENT NUMBER: 119:125045
TITLE: A spectroscopic investigation of Losartan polymorphs
AUTHOR(S): Raghavan, Krishnaswamy; Dwivedi, Anil; Campbell, G. Creston, Jr.; Johnston, Eric; Levorse, Dorothy; McCauley, James; Hussain, Munir
CORPORATE SOURCE: Exp. Stn., Du Pont Merck Pharm. Co., Wilmington, DE, 19880-0400, USA
SOURCE: Pharmaceutical Research (1993), 10(6), 900-4
CODEN: PHREEB; ISSN: 0724-8741
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Losartan (I), an antihypertensive agent in clin. development, existed in 2 enantiotropic polymorphic forms, a low-temperature stable form (Form I) and a high-temperature stable form (Form II), the temps. at which they are stable being related to the transition temperature X-ray powder diffraction patterns indicated differences in the crystal packing of the 2 forms. The vibrational data from IR and Raman spectroscopy suggested a subtle change in mol. conformation and crystal packing in the 2 forms. Solid-state 13C NMR data of the polymorphs concurred with the vibrational data and indicated that, while the observed line widths reflect no major changes in crystallinity, signal multiplicities and chemical shifts do reflect differences in mol. packing in the resp. unit cells. Thus, in the absence of crystallog. data, useful structural information could be derived from spectroscopic results to identify each of the crystalline forms.